Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD.
Ford
Paul A
PA
Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, England. p.ford@imperial.ac.uk
Durham
Andrew L
AL
Russell
Richard E K
RE
Gordon
Fabiana
F
Adcock
Ian M
IM
Barnes
Peter J
PJ
D000280:Administration, Inhalation; D000284:Administration, Oral; D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D002214:Capsules; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D056464:Histone Deacetylase 2 / Q000032:analysis; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000201:enzymology; D012129:Respiratory Function Tests; D013183:Sputum / Q000737:chemistry; D013806:Theophylline / Q000008:administration & dosage*; D016896:Treatment Outcome
D000730:Androstadienes; D001993:Bronchodilator Agents; D002214:Capsules; D013806:Theophylline; D000068298:Fluticasone; C533423:HDAC2 protein, human; D056464:Histone Deacetylase 2